Savolitinib

Imfinzi (durvalumab) is a PD-L1 inhibitor used in various cancer treatments, including NSCLC, SCLC, biliary tract cancer, and endometrial cancer. AstraZeneca, a global biopharmaceutical company, focuses on oncology, rare diseases, and bio-pharmaceuticals, aiming to redefine cancer care and eliminate it as a cause of death.

Imfinzi (durvalumab) is a PD-L1 inhibitor used in various cancer treatments, including NSCLC, SCLC, biliary tract cancer, and endometrial cancer. AstraZeneca is a leader in oncology, focusing on early detection and innovative treatments for lung cancer and immuno-oncology, aiming to redefine cancer care and eliminate it as a cause of death.

Hutchmed renews contract with China's NHSA; Orpathys (savolitinib), an oral MET TKI for NSCLC with MET exon 14 skipping alterations, remains in the NRDL until Jan 1, 2025, under current terms. Orpathys, jointly developed by Hutchmed and AstraZeneca, is the first selective MET inhibitor in China and the NRDL.

HUTCHMED announces renewal of ORPATHYS® (savolitinib) inclusion in China's National Reimbursement Drug List (NRDL) effective January 1, 2025, maintaining current terms. ORPATHYS®, an oral MET TKI, received conditional approval in China in 2021 for treating NSCLC with MET exon 14 skipping alterations. The NRDL inclusion aims to improve drug affordability, covering 95% of China's population.

Lung cancer, primarily non-small cell lung cancer (NSCLC), is a leading cause of morbidity and mortality globally. Targeted therapies have emerged as a preferred first-line treatment for NSCLC patients with oncogenic driver mutations, such as EGFR, ALK, ROS1, BRAF, MET, RET, FGFR, and NTRK. These therapies, including small-molecule drugs and monoclonal antibodies, have shown superior efficacy compared to traditional chemotherapy and immunotherapy, particularly in specific molecular subtypes. Challenges remain in drug resistance, adverse effects, and determining optimal treatment sequences. Continued research is essential for advancing precision medicine in lung cancer treatment.

Lung cancer is a leading cause of cancer death globally, with NSCLC being the most common type. LAURA is a Phase III trial testing Tagrisso, a third-generation EGFR-TKI, in Stage III EGFRm NSCLC patients. Tagrisso has shown efficacy in various stages of NSCLC and is part of AstraZeneca's comprehensive lung cancer portfolio. The company aims to redefine cancer care and eliminate it as a cause of death.

At the 2024 WCLC, 7,000+ clinicians and scientists gathered to review impactful abstracts on lung cancer treatments, including novel perioperative strategies for resectable lung cancer and the use of tyrosine kinase inhibitors, bispecific antibodies, and ADCs in advanced NSCLC and SCLC. Key findings included superior event-free survival with perioperative nivolumab, high pathologic response rates with ADCs in localized NSCLC, and promising outcomes with EGFR-MET bispecific antibodies and HER2-targeted therapies. The conference also highlighted the potential of ADCs in SCLC and the need for improved biomarker development and patient selection tools.

AstraZeneca and Daiichi Sankyo submitted a new BLA for datopotamab deruxtecan for EGFR-mutated NSCLC, withdrawing a previous BLA for nonsquamous NSCLC. The decision was based on FDA feedback and trial data showing pronounced benefits for EGFR-mutated patients.

Datopotamab deruxtecan, an investigational TROP2-directed ADC, is being evaluated in multiple clinical trials for advanced NSCLC, including TROPION-Lung05, TROPION-Lung01, and TROPION-PanTumor01. These trials assess efficacy and safety in patients with actionable genomic alterations and those requiring systemic therapy following prior treatment. Primary endpoints include objective response rate (ORR) and progression-free survival (PFS). AstraZeneca and Daiichi Sankyo collaborate on the development and commercialization of datopotamab deruxtecan.

ESMO Congress 2024 showcased PIONeeR trial addressing PD-1/PD-L1 resistance in NSCLC, Rome trial's genomic-guided therapy improving outcomes in metastatic solid tumors, and Prov-GigaPath AI model for cancer mutation prediction and tumor microenvironment analysis.